Selective and nonselective dopamine receptor agonists: An innovative approach to cardiovascular disease treatment

American Heart Journal

Volumn 132, Issue 4, 1996, Pages 861-870

  Frishman, William H ^a,b   Hotchkiss, Hilary ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3,4 DIHYDROXYPHENYL) 1,2,3,4 TETRAHYDRO 7,8 DIHYDROXYISOQUINOLINE; BROMOCRIPTINE; CABERGOLINE; CARMOXIROLE; DIHYDROERGOTOXINE; DOCARBOMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPEXAMINE; FENOLDOPAM; FPL 63012 AR; GAMMA GLUTAMYLDOPA; IBOPAMINE; NORADRENALIN; QUINPIROLE; ROPINIROLE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DYSPEPSIA; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NORADRENALIN RELEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TACHYCARDIA; VOMITING;

EID: 0029960462     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90323-3     Document Type: Article

References (57)

1. Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharm Rev 1972;24:1-29.
2. Goldberg LI, Kohli JD, Glock D. Conclusive evidence for two subtypes of dopamine receptors. In, Woodruff GN, Poat JA, Roberts PJ, editors. Dopaminergic systems and their regulation. London: MacMillan, 1986;195-212.
3. Van Veldhuisen DJ, Girbes ARJ, deGraeff PA, Lie KI. Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure. Intl J Cardiol 1992;37:293-300.
4. Girbes ARJ, Smit AJ, Meijer S, Reitsma WD. Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron 1990;56:179-85.
5. 1 receptor agonist (fenoldopam) in patients with congestive heart failure. Am Heart J 1988;116:473-9.
6. Gollub SB, Elkayani U, Young JB, Miller LW, Haffey KA. Efficacy and safety of a short-term (6 h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study. J Am Coll Cardiol 1991;18:383-90.
7. Meyer W, Buhring KU, Steiner K, Ungethum W, Schnurr E. Pharniacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist. Eur Heart J 1992;13(suppl D): 121-8.
8. Pouleur H, Raigoso J, Rousseau MF. Dopaminergic drugs in the management of chronic heart failure. Eur Heart J 1991;12(suppl C):29-34.
9. Carey RM. Dopamine, hypertension and the potential for agonist therapy. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management, 2nd ed. New York: Raven Press, 1995:2937-52.
10. Francis GS. Receptor systems involved in norepinephrine release in heart failure: focus on dopaminergic systems. Clin Cardiol 1995;18(suppl I):I-13-6.
11. Goldberg LI, Kohli JD. Peripheral pre- and post-synaptic dopamine receptors: are they different from the receptors in the central nervous system? Commun Psychopharm 1979;3:447-56.
12. Lee MR: Dopamine and the kidney, 10 years on. Clin Sci 1993;84:357-75.
13. 2 receptor agonists are necessary to inhibit Na+/K+ ATPase activity in proximal tubules from the rat kidney. Acta Physiol Scand 1988;132:441-3.
14. Bertorello A, Aperia A. Regulation of Na+/K+ ATPase activity in kidney proximal tubules: involvement of GTP binding proteins. Am J Physiol 1989;256:F57-62.
15. Gesek FA, Schoolwerth AC. Hormonal interactions with the Na+/K+ exchanger. Am J Physiol 1990;258:F514-21.
16. 1 receptor agonist augments regional myocardial blood flow: comparison of fenoldopam and dopamine. Am Heart J 1992;124: 418-23.
17. Goldberg LI, Murphy MB. Dopamine. In: Messerli FH, editor. Cardiovascular drug therapy. Philadelphia: W.B. Saunders, 1990;1083-9.
18. Lokhandwala MF, Hedge SS. Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure. Am J Med 1991;90(suppl 5B):2S-9S.
19. Carey RM, Thorner MO, Ortt EM. Dopaminergic inhibition of metoclopramide induced aldosterone secretion in man: dissociation of responses to dopamine and bromocriptine. J Clin Invest 1980;66:10-8.
20. Haeusler G, Lues I, Minck KO, Schelling P, Seyfried CA. Pharmacological basis for antihypertensive therapy with a novel dopamine agonist. Eur Heart J 1992;13(suppl D):129-35.
21. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Goodwin AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press, 1990:187-220.
22. Ventresca GP, Lodola E. Clinical pharmacokinetica of ibopamine on different diseases and conditions. Arzneim Forsch 1988;38(8):1175-80.
23. Metra M, Die Cas L. Clinical efficacy of ibopamine in patients with chronic heart failure. Clin Cardiol 1995;18(suppl I):I-22-31.
24. Girbes ARJ, van Veldhuisen DJ, Smit AJ. Dopamine agonists, a new perspective in cardiovascular therapy? Netherlands J Med 1991;39:65-71.
25. Pouleur H. Neurohumoral and hemodynamic effects of ibopamine. Clin Cardiol 1995;18(suppl I):I-17-21.
26. Sher D, Licciardello L, Ferrari V, Sirtori F, Cesana B. Safety of ibopamine therapy in congestive heart failure. Arzneim Forsch 1991; 41(4):402-9.
27. Dalla Volta S, Razzolini R, Roshan-Ali Y. Clinical efficacy of ibopamine in heart failure. Results of a double-blind clinical study. Am J Non-Invasive Cardiol 1991;5(suppl 1):15-8.
28. Van Veldhuisen DJ, Man in't Veld AJ, Dunselman PHJM, Lok DJA, Dohman HJM, Poortermans JC, et al. on behalf of the DIMT Study Group. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993;22:1564-73.
29. Barabino A, Galbariggi G, Pizzorni C, Lotti G. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology 1991;78:243-56.
30. Itoh H. Clinical pharmacology of ibopamine. Am J Med 1991;90(suppl 5B):36S-42S.
31. Van Veldhuisen DJ, Brower J, Man in't Veld AJ, Dunselman PH, Boomsa F, Lie KI. Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT study group. Am J Cardiol 1995;75:796-800.
32. van Veldhuisen DJ, Girbes ARJ, van den Broek SAJ, de Graeff PA, van Glist WH, Lie KI. Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure. Am J Cardiol 1993;71:992-4.
33. Die Gas L, Metra M, Visioli O. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. Am J Cardiol 1992;70:629-34.
34. Lieverse AG, Girbes AR, Van Veldhuisen DJ, Smit AJ, Zijlstra JG, Meijer S, et al. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. Eur Heart J 1995;16: 937-42.
35. Spencer C, Faulds D, Fitton A. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Drugs & Aging 1993;3(6):556-84.
36. Die Cas L, Metra M, Nodari S, Riva S, Manca C, Visoli O. Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. Cardiovasc Drugs & Ther 1988; 2:221-9.
37. Caponnetto S, Terrachini V, Bruzzone F, Masperone MA, Pastorino L, Licciardello L, et al. Long-term treatment of congestive heart failure with oral ibopamine. Effects on rhythm disorders and neurohumoral alterations. Cardiology 1990;77(suppl 5):43-8.
38. Young JB, Leon CA. Fenoldopam. In: Messerli FH, editor. Cardiovascular drug therapy. Philadelphia: W.B. Saunders, 1990;1138-48.
39. Pilmer BL, Green JA, Panacek EA, Elliot WJ, Murphy MB, Rutherford W, et al. Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. J Clin Pharmacol 1993;33:549-53.
40. 1 agonist fenoldopam. Circulation 1987;76:1312-8.
41. Ventura HO, Messerli FH, Frohlich ED, Kobrin I, Oigman W, Dunn FG, et al. Immediate hemodynamic effects of a dopamine receptor agonist (fenoldopam) in patients with essential hypertension. Circulation 1984;69:1142-5.
42. Hackman BB, Griffin B, Mills M, Ramanathan KB. Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension. Am J Cardiol 1992; 69:918-22.
43. Welch M, Newstead CG, Smyth JV, Dodd PG, Walker MG. Evaluation of dopexamine hydrochloride as a renoprotective agent during aortic surgery. Ann Vasc Surg 1995;9:488-92.
44. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol 1995;35:747-62.
45. Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitro-prusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993;95:161-8.
46. Elliott WJ, Karnezis TA, Silverman RA, Geanon J, Tripathi RC, Murphy MB. Intraocular pressure increases with fenoldopam but not nitroprusside in hypertensive humans. Clin Pharmacol Ther 1991; 49:285-93.
47. MacGregor DA, Butterworth JF IV, Zaloga GP, Prielipp RC, James R, Royster RL. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 1994;106(3):835-41.
48. Panacek EA, Bednarczyk EM, Dunbar LM, Foulke GE, Holcslaw TL. Randomized prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group. Acad Emerg Med 1995;2:959-65.
49. Tan LB, Littler WA, Murray RG. Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure. Int J Cardiol 1991;30:203-8.
50. Napoleone P, Ricci A, Ferrante F, Amenta F. Dopexamine hydrochloride in the human heart: receptor binding and effects on cAMP generation. Eur Heart J 1992;13:1709-17.
51. Quinn N, Hilas A, Hermitte FL, Agid Y. Bromocriptine in Parkinson's disease: a study of cardiovascular effects. J Neurol Neurosurg Psych 1981;44:426-9.
52. Walden RJ, Hernandez J, Bhattacharjee P, Graham B, Prichard BN. Bromocriptine in the treatment of hypertension. Eur J Clin Pharmacol 1986;30:141-4.
53. Lahlou S, Duarte GP, Demenge P. Entrai dopaminergic origin of bromocriptine induced tachycardia in normotensive rats. Cardiovasc Res 1993;27:2022-7.
54. Eickman FM. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin Cardiol 1992;15:781-3.
55. 1 agonists: 4-(3,4-dihydroxy-phenyl)-1,2,3,4-tetrahydroisoquinoline derivates. Chem Pharm Bull 1991;39:2910-4.
56. Smith GW, Farmer JB, Ince F, Matu K, Mitchell PD, Naya I, et al. FPL 63012AR: a potent Di-receptor agonist. Br J Pharmacol 1990;100:295-300.
57. Lee MR. Five years' experience with gamma-L-glutamyl-L-Dopa: a relatively renally specific dopaminergic prodrug in man. J Auton Pharmacol 1990;10(suppl I):s103-8.